



(51) International Patent Classification:

C12Q 1/68 (2006.01) *C07K 16/30* (2006.01)
A61K 39/395 (2006.01) *C12N 15/113* (2010.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/SG2010/000072

(22) International Filing Date:

2 March 2010 (02.03.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/156,819 2 March 2009 (02.03.2009) US

(71) Applicant (for all designated States except US): **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis, Singapore 138632 (SG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DESAI, Kartik, V** [IN/SG]; Genome Institute of Singapore, 60 Biopolis Way, #02-01, Singapore 138672 (SG). **LIU, Edison T** [US/SG]; Genome Institute of Singapore, 60 Biopolis Way, #02-01, Singapore 138672 (SG). **MILLER, Lance, David** [US/US]; Wake Forest University School of Medicine, Department of Cancer Biology, Medical Center Drive, 4th Floor Hanes Building, Winston Salem, NC 27157 (US).

(74) Agent: **YU SARN AUDREY & PARTNERS**; 17 Upper Circular Road, #03-00 Jura Building, Singapore 058415 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

[Continued on next page]

(54) Title: A BIOMARKER AND TREATMENT FOR CANCER

Figure 1



(57) Abstract: A correlation between expression of JMJD6 polypeptide and breast cancer metastasis exists accordingly the present invention relates a diagnostic, prognostic and therapeutic biomarker to distinguish between early and advanced/metastatic cancer particularly breast cancer, including compounds and methods to treat the same.



Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))